Cost-effectiveness analysis of valsartan versus losartan and the effect of switching

References

• Nixon RM, Muller E, Lowy A, et al. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract 2009;63:766-75
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Zhang J, Wu EQ, et al. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension. Curr Med Res Opin 2010;26:849-60
   PubMed Web of Science ®Google Scholar
• Aronow HD, Hess G, Hill J, et al. Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. Am J Ther 2010;17:167-75
   PubMed Web of Science ®Google Scholar
• Asara JM, Schweitzer MH, Freimark LM, et al. Protein sequences from mastodon and Tyrannosaurus rex revealed by mass spectrometry. Science 2007;316:280-5
   PubMed Web of Science ®Google Scholar
• Verbeeck RK, Kanfer I, Walker RB. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy. Eur J Pharm Sci 2006;28:1-6
   PubMed Web of Science ®Google Scholar
• Wilson PW, Bozeman SR, Burton TM, et al. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation 2008;118:124-30
   PubMed Web of Science ®Google Scholar
• Arias E. United States life tables, 2004. Natl Vital Stat Rep 2007;56:1-39
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data (NHANES). Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2005–2006, 2006. http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/nhanes05_06.htm. Accessed January 15, 2009
   Google Scholar
• National Institutes of Health (NIH), National Heart L, and Blood Institute. The Sixth Report of the Joint National Committee (JNC-6) on prevention, detection, evaluation, and treatment of high blood pressure. No. 98–4080. NIH. 1997, Bethesda, MD.
   Google Scholar
• Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care 1998;4:1563-8
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181
   PubMed Web of Science ®Google Scholar
• Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality, Maryland. The HCUP State Inpatient Database (SID). New Jersey: Agency for Healthcare Research and Quality, 2008
   Google Scholar
• Massachusetts Division of Health Care Finance and Policy. Massachusetts Fiscal Year 2008 acute hospital case mix data base, level III. Massachusetts: Division of Health Care Finance and Policy, 2008
   Google Scholar
• Office of Statewide Health Planning and Development. Inpatient 2008. Discharge Data (Version A). California: Office of Statewide Health Planning and Development, 2008
   Google Scholar
• St. Paul Computer Center Inc. Inpatient research use file. Baltimore, MD: St. Paul Computer Center Inc., 2008
   Google Scholar
• State of Florida, Agency for Health Care Administration, State Center for Health Statistics. Hospital patient data file. Florida: Agency for Health Care Administration, State Center for Health Statistics, 2008
   Google Scholar
• Washington State Department of Health, Office of Hospital and Patient Data. CHARS (Comprehensive Hospital Abstract Reporting System) Public Data File. Washington: Washington State Department of Health, Office of Hospital and Patient Data, 2008
   Google Scholar
• Lindgren-Furmaga EM, Schuna AA, Wolff NL, et al. Cost of switching hypertensive patients from enalapril maleate to lisinopril. Am J Hosp Pharm 1991;48:276-9
   PubMedGoogle Scholar
• Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998;81:1110-5
   PubMed Web of Science ®Google Scholar
• Thomson PDR. Micromedex Red Book for Windows. Version 61127, 2010
   Google Scholar
• Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20
   PubMed Web of Science ®Google Scholar
• Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005;8:581-90
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Davis BR, Cutler JA, et al. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Gen Intern Med 2008;23:509-16
   PubMed Web of Science ®Google Scholar
• Johnston A. Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. Curr Med Res Opin 2010;26:871-8
   PubMed Web of Science ®Google Scholar
• Johnston A, Stafylas P, Stergiou GS. Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol 2010;70:320-34
   PubMed Web of Science ®Google Scholar
• Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12:239-45
   PubMed Web of Science ®Google Scholar